It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to discuss the unmet needs in the treatment vulvovaginal candidiasis.
The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with Recurrent Vulvovaginal Candidiasis’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- Could you give us an overview of the health burden of vulvovaginal candidiasis (VVC)? (0:05)
- What are the unmet needs in the treatment of VVC? (1:37)
Disclosures: Mahmoud Ghannoum is contracted to conduct research from Mycovia pharmaceuticals, Scynexis, Amplyx Pharma, Gilead and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
